Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Recent Articles in Free Articles

Week in Review: Jemicare Out-licenses Prostate Cancer Therapy to Roche for $650 Million
Week in Review: AIM Vaccine Stages $20 Million IPO on Hong Kong Exchange
Week in Review: YishengBio to List on NASDAQ via SPAC Merger at an $834 Million Value
Week in Review: Sino Biopharm Subsidiary Enters $307 Million Agreement for Rights to NASH Candidate
Week in Review: METiS, a US-China AI biotech, Acquires Pan-RAF Inhibitor in $482 Million Deal
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
July 27-31, 2022